< Back to Article

Analysis of Individual Protein Regions Provides Novel Insights on Cancer Pharmacogenomics

Figure 4

PFR perturbations identified using data from cell lines predict the survival of patients treated with Irinotecan.

(a) Proteins with PFR associated to Irinotecan resistance can not be used to successfully stratify cancer patients treated with this drug, as there are no differences between patients with mutations in such proteins (gray) and those without them (black) (b) Specific PFR in these proteins do predict the outcome of cancer patients. Patients with mutations altering the PFRs found using CCLE (red) have worse outcomes that those with mutations in other regions of the same protein (green) or no mutations (black).

Figure 4